Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity

Area of Science:

• Drug Discovery and Development
• Pharmacology
• Toxicology

Background:

• Small-molecule drug development faces low success rates, with safety concerns being a major cause of attrition.
• Promiscuous binding to multiple targets can lead to unexpected adverse effects and clinical trial failures.
• Early identification of compounds with low toxicity potential is crucial for improving drug discovery success.

Purpose of the Study:

• To develop and validate a small-scale, cost-effective promiscuity panel (PP) for early assessment of drug candidate safety.
• To evaluate the relationship between compound properties (lipophilicity, basicity, molecular weight) and target promiscuity.
• To correlate promiscuity profiling with in vitro and in vivo toxicity data.

Main Methods:

• Construction of a small-scale promiscuity panel (PP) with eight diverse targets (ROCK1, PDE4D2, GR, PPARγ, 5-HT2B, adenosine A3, M1, and GABA(A)).
• Validation of the PP by comparing its promiscuity index with larger-scale panels.
• Analysis of compound properties influencing promiscuity and correlation with cytotoxicity and in vivo toxicity data.

Main Results:

• The PP effectively predicted compound promiscuity, correlating with larger-scale panel assessments.
• Lipophilicity and basicity were identified as key factors increasing promiscuity; molecular weight showed no significant contribution.
• Promiscuity assessed by the PP correlated with both in vitro cytotoxicity and in vivo toxicity.

Conclusions:

• The developed small-scale promiscuity panel is a valid and cost-effective tool for early-stage drug discovery.
• Utilizing this PP can help identify compounds with a reduced likelihood of causing toxicity concerns.
• This approach has the potential to decrease drug attrition rates attributed to safety issues in clinical studies.